RAD51C/D, MSH6); and multiple common but low pentrance susceptibility alleles identified by GWAS.
32
RAD51C/D, MSH6); and multiple common but low pentrance susceptibility alleles identified by GWAS.
33
Identifying genetic risk alleles for ovarian cancer has had a significant impact on disease prevention 34 strategies; for example it is now routine clinical practice for individuals with germline BRCA1 and
35
BRCA2 mutations to undergo risk reducing salpingo-oophorectomy. Because ovarian cancers are 36 commonly diagnosed at a late clinical stage when the prognosis is poor, the continued development of 37 genetic risk prediction and prevention strategies will represent an important approach to reduce 38 2 mortality due to ovarian cancer. Advances in genomics technologies that enable more high-throughout 39 genetic testing, combined with research studies that identify additional EOC risk alleles will likely 40 provide further opportunities to establish polygenic risk prediction approaches, based on combinations 41 of rare high/moderate penetrance susceptibility genes and common, low penetrance susceptibility factors to identify women at greatest risk of EOC in the population, followed by effective clinical 75 intervention strategies could represent a powerful population based strategy to reduce mortality 
26
Several studies have reported that risks of ovarian and breast cancer vary depending on the location 27 of the predicted pathogenic mutation in both BRCA1 and BRCA2 [38] [39] [40] [41] [42] . A recent study of ~12,000
28
BRCA1 carriers and 7,000 BRCA2 carriers with breast and/or ovarian cancer indicated there are 29 6 increases in ovarian cancer risks with a concomitant decrease in breast cancer risk for mutations in 30 the central portion both BRCA1 and BRCA2 [32, [38] [39] [40] [41] [42] 
61
Common low penetrance susceptibility alleles: There has been substantial progress in identifying 62 common risk variants for ovarian cancer using genome wide association studies (GWAS). These 63 studies have so far identified thirty-nine independant EOC risk regions (Table 1) (Table 1) , demonstrating the significant amount of biology yet to 87 be identified.
88
Missing Heritability: The studies summarized above report on a range of susceptibility genes and risk 89 alleles for ovarian cancer of both varying allele frequency and risks in the population (Figure 3) .
90
However, the known susceptibility genes for ovarian cancer account for ~40% of the excess familial 91 risks (narrow sense heritability), with common low risk variants found by GWAS contributing less than 92 5% [82] (Figure 4) 
16

Clincial Risk Predicton and Prevention of Epithelial Ovarian Cancers
17
One of the successful advances in reducing EOC mortality over the last few years has come from 18 identifying germline genetic variants that substantially increase a woman's lifetime risk of disease. As (e.g. PALB2, BARD1, NBN) [56] 
49
The clincial utility of genetic data is further hampered by the lack of functional 'proof' that germine 
95
One recent study estimated the impact on the risk estimates of BRIP1 mutation carriers after 96 incorporating additional genetic and epidemiological risk factor information [56] . Assuming the best 97 estimate to be the point estimate from segregation analysis performed in familes carrying BRIP1 98 mutations, the lifetime risk of epithelial ovarian cancer in BRIP1 carriers was estimated to be 5.8%. 
